4.2 Review

TDM in psychiatry and neurology: A comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians

Journal

WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY
Volume 19, Issue 3, Pages 162-174

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1080/15622975.2018.1439595

Keywords

Therapeutic drug monitoring; pharmacokinetics; neuropsychopharmacology; drug therapy; pharmacovigilance

Categories

Funding

  1. AstraZeneca
  2. Bristol-Myers Squibb
  3. Janssen
  4. Lilly
  5. Otsuka
  6. Pfizer
  7. Servier
  8. German Federal Institute for Drugs and Medical Devices
  9. Cephalon
  10. Essex
  11. Janssen Cilag
  12. Lundbeck
  13. Schering-Plough
  14. Wyeth
  15. Alkermes
  16. Eli Lilly
  17. Johnson Johnson
  18. Merz
  19. Bayer Vital Health Care
  20. AlcaSynn
  21. Bio-Rad
  22. Mundipharma
  23. Novartis

Ask authors/readers for more resources

Objectives: Therapeutic drug monitoring (TDM) combines the quantification of drug concentrations in blood, pharmacological interpretation and treatment guidance. TDM introduces a precision medicine tool in times of increasing awareness of the need for personalized treatment. In neurology and psychiatry, TDM can guide pharmacotherapy for patient subgroups such as children, adolescents, pregnant women, elderly patients, patients with intellectual disabilities, patients with substance use disorders, individuals with pharmacokinetic peculiarities and forensic patients. Clear indications for TDM include lack of clinical response in the therapeutic dose range, assessment of drug adherence, tolerability issues and drug-drug interactions.Methods: Based upon existing literature, recommended therapeutic reference ranges, laboratory alert levels, and levels of recommendation to use TDM for dosage optimization without specific indications, conversion factors, factors for calculation of dose-related drug concentrations and metabolite-to-parent ratios were calculated.Results: This summary of the updated consensus guidelines by the TDM task force of the Arbeitsgemeinschaft fur Neuropsychopharmakologie und Pharmakopsychiatrie offers the practical and theoretical knowledge for the integration of TDM as part of pharmacotherapy with neuropsychiatric agents into clinical routine.Conclusions: The present guidelines for TDM application for neuropsychiatric agents aim to assist clinicians in enhancing safety and efficacy of treatment.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available